Cancer genetics and genomics of human FOX family genes

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 198-206

  Katoh, Masuko ^a   Igarashi, Maki ^b   Fukuda, Hirokazu ^b   Nakagama, Hitoshi ^b   Katoh, Masaru ^b  

^a M&M Medical BioInformatics   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

FOX; Germ line variation; Nuclear hormone receptor; Pioneer factor; Somatic mutation

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 1; MICRORNA 200B; MICRORNA 34A; MICRORNA 504; MYC PROTEIN; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN 2; SONIC HEDGEHOG PROTEIN; THYROID TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXA1; TRANSCRIPTION FACTOR FOXF1; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR FOXR1; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANAPLASTIC THYROID CANCER; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; DOWN REGULATION; ENZYME DEGRADATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE FUNCTION; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENOMICS; HUMAN; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG CANCER; MARGINAL ZONE LYMPHOMA; MULTIGENE FAMILY; NEUROBLASTOMA; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CANCER; TRANSCRIPTION REGULATION; UPREGULATION;

ERINACEIDAE;

EID: 84870376109     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.017     Document Type: Review

References (130)

1. Carlsson P., Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev. Biol. 2002, 250:1-23.
2. Lehmann O.J., Sowden J.C., Carlsson P., Jordan T., Bhattacharya S.S. Fox's in development and disease. Trends Genet. 2003, 19:339-344.
3. Katoh M., Katoh M. Human FOX gene family. Int. J. Oncol. 2004, 25:1495-1500.
4. Hannenhalli S., Kaestner K.H. The evolution of Fox genes and their role in development and disease. Nat. Rev. Genet. 2009, 10:233-240.
5. Benayoun B.A., Caburet S., Veitia R.A. Forkhead transcription factors: key players in health and disease. Trends Genet. 2011, 27:224-232.
6. Weigel D., Jürgens G., Küttner F., Seifert E., Jäckle H. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell 1989, 57:645-658.
7. Lai E., Clark K.L., Burley S.K., Darnell J.E. Hepatocyte nuclear factor 3/fork head or "winged helix" proteins: a family of transcription factors of diverse biologic function. Proc. Natl. Acad. Sci. USA 1993, 90:10421-10423.
8. Clark K.L., Halay E.D., Lai E., Burley S.K. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 1993, 364:412-420.
9. van Dongen M.J., Cederberg A., Carlsson P., Enerback S., Wikstrom M. Solution structure and dynamics of the DNA-binding domain of the adipocyte-transcription factor FREAC-11. J. Mol. Biol. 2000, 296:351-359.
10. Pierrou S., Hellqvist M., Samuelsson L., Enerbäck S., Carlsson P. Cloning and characterization of seven human forkhead proteins: binding site specificity and DNA bending. EMBO J. 1994, 13:5002-5012.
11. Fujii Y., Nakamura M. FOXK2 transcription factor is a novel G/T-mismatch DNA binding protein. J. Biochem. 2010, 147:705-709.
12. Almeida M., Han L., Martin-Millan M., O'Brien C.A., Manolagas S.C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from TCF- to FoxO-mediated transcription. J. Biol. Chem. 2007, 282:27298-27305.
13. Roesch A., Mueller A.M., Stempfl T., Moehle C., Landthaler M., Vogt T. RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int. J. Cancer 2008, 122:1047-1057.
14. Brenkman A.B., van den Broek N.J., de Keizer P.L., van Gent D.C., Burgering B.M. The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response. FASEB J. 2010, 24:4271-4280.
15. Fisher S.E., Scharff C. FOXP2 as a molecular window into speech and language. Trends Genet. 2009, 25:166-177.
16. Newbury D.F., Monaco A.P. Genetic advances in the study of speech and language disorders. Neuron 2010, 68:309-320.
17. Stankiewicz P., Sen P., Bhatt S.S., Storer M., Xia Z., Bejjani B.A., Ou Z., Wiszniewska J., Driscoll D.J., Maisenbacher M.K., Bolivar J., Bauer M., et al. Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other malformations. Am. J. Hum. Genet. 2009, 84:780-791.
18. Manning A.K., Hivert M.F., Scott R.A., Grimsby J.L., Bouatia-Naji N., Chen H., Rybin D., Liu C.T., Bielak L.F., Prokopenko I., Amin N., Barnes D., et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat. Genet. 2012, 44:659-669.
19. Li C.S., Chae S.C., Lee J.H., Zhang Q., Chung H.T. Identification of single nucleotide polymorphisms in FOXJ1 and their association with allergic rhinitis. J. Hum. Genet. 2006, 51:292-297.
20. Willcox B.J., Donlon T.A., He Q., Chen R., Grove J.S., Yano K., Masaki K.H., Willcox D.C., Rodriguez B., Curb J.D. FOXO3A genotype is strongly associated with human longevity. Proc. Natl. Acad. Sci. USA 2008, 105:13987-13992.
21. Jin Y., Birlea S.A., Fain P.R., Mailloux C.M., Riccardi S.L., Gowan K., Holland P.J., Bennett D.C., Wallace M.R., McCormack W.T., Kemp E.H., Gawkrodger D.J., et al. Common variants in FOXP1 are associated with generalized vitiligo. Nat. Genet. 2010, 42:576-578.
22. Böttcher Y., Tönjes A., Enigk B., Scholz G.H., Blüher M., Stumvoll M., Kovacs P. A SNP haplotype of the forkhead transcription factor FOXO1A gene may have a protective effect against type 2 diabetes in German Caucasians. Diabetes Metab. 2007, 33:277-283.
23. Müssig K., Staiger H., Machicao F., Stancáková A., Kuusisto J., Laakso M., Thamer C., Machann J., Schick F., Claussen C.D., Stefan N., Fritsche A., et al. Association of common genetic variation in the FOXO1 gene with β-cell dysfunction, impaired glucose tolerance, and type 2 diabetes. J. Clin. Endocrinol. Metab. 2009, 94:1353-1360.
24. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
25. Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol. Ther. 2007, 6:832-839.
26. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
27. Sagaert X., de Wolf-Peeters C., Noels H., Baens M. The pathogenesis of MALT lymphomas: where do we stand?. Leukemia 2007, 21:389-396.
28. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
29. Dansen T.B., Burgering B.M. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008, 18:421-429.
30. Lin L., Miller C.T., Contreras J.I., Prescott M.S., Dagenais S.L., Wu R., Yee J., Orringer M.B., Misek D.E., Hanash S.M., Glover T.W., Beer D.G. The hepatocyte nuclear factor 3 α gene, HNF3α (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 2002, 62:5273-5279.
31. Hu X., Stern H.M., Ge L., O'Brien C., Haydu L., Honchell C.D., Haverty P.M., Peters B.A., Wu T.D., Amler L.C., Chant J., Stokoe D., et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 2009, 7:511-522.
32. Nucera C., Eeckhoute J., Finn S., Carroll J.S., Ligon A.H., Priolo C., Fadda G., Toner M., Sheils O., Attard M., Pontecorvi A., Nose V., et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin. Cancer Res. 2009, 15:3680-3689.
33. Robbins C.M., Tembe W.A., Baker A., Sinari S., Moses T.Y., Beckstrom-Sternberg S., Beckstrom-Sternberg J., Barrett M., Long J., Chinnaiyan A., Lowey J., Suh E., et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011, 21:47-55.
34. C.S. Grasso, Y.M. Wu, D.R. Robinson, X. Cao, S.M. Dhanasekaran, A.P. Khan, M.J. Quist, X. Jing, R.J. Lonigro, J.C. Brenner, I.A. Asangani, B. Ateeq, et al., The mutational landscape of lethal castration-resistant prostate cancer, Nature, in press.
35. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Gräf S., Ha G., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
36. Laganière J., Deblois G., Lefebvre C., Bataille A.R., Robert F., Giguère V. From the cover: location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. USA 2005, 102:11651-11656.
37. Schneider J., Ruschhaupt M., Buness A., Asslaber M., Regitnig P., Zatloukal K., Schippinger W., Ploner F., Poustka A., Sültmann H. Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. Int. J. Cancer 2006, 119:2974-2979.
38. van der Heul-Nieuwenhuijsen L., Dits N.F., Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 2009, 103:1574-1580.
39. Friedman J.R., Kaestner K.H. The Foxa family of transcription factors in development and metabolism. Cell. Mol. Life Sci. 2006, 63:2317-2328.
40. Cirillo L.A., Lin F.R., Cuesta I., Friedman D., Jarnik M., Zaret K.S. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 2002, 9:279-289.
41. Sekiya T., Muthurajan U.M., Luger K., Tulin A.V., Zaret K.S. Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev. 2009, 23:804-809.
42. Hirai H., Tani T., Kikyo N. Structure and functions of powerful transactivators: VP16, MyoD and FoxA. Int. J. Dev. Biol. 2010, 54:1589-1596.
43. Sérandour A.A., Avner S., Percevault F., Demay F., Bizot M., Lucchetti-Miganeh C., Barloy-Hubler F., Brown M., Lupien M., Métivier R., Salbert G., Eeckhoute J. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011, 21:555-565.
44. Zaret K.S., Watts J., Xu J., Wandzioch E., Smale S.T., Sekiya T. Pioneer factors, genetic competence, and inductive signaling: programming liver and pancreas progenitors from the endoderm. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:119-126.
45. Magnani L., Eeckhoute J., Lupien M. Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet. 2011, 27:465-474.
46. Gao N., Zhang J., Rao M.A., Case T.C., Mirosevich J., Wang Y., Jin R., Gupta A., Rennie P.S., Matusik R.J. The role of hepatocyte nuclear factor-3 α (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 2003, 17:1484-1507.
47. Zhang C., Wang L., Wu D., Chen H., Chen Z., Thomas-Ahner J.M., Zynger D.L., Eeckhoute J., Yu J., Luo J., Brown M., Clinton S.K., et al. Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 2011, 71:6738-6748.
48. Thorat M.A., Marchio C., Morimiya A., Savage K., Nakshatri H., Reis-Filho J.S., Badve S. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J. Clin. Pathol. 2008, 61:327-332.
49. Sahu B., Laakso M., Ovaska K., Mirtti T., Lundin J., Rannikko A., Sankila A., Turunen J.P., Lundin M., Konsti J., Vesterinen T., Nordling S., et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011, 30:3962-3976.
50. Green M.R., Aya-Bonilla C., Gandhi M.K., Lea R.A., Wellwood J., Wood P., Marlton P., Griffiths L.R. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosom. Cancer 2011, 50:313-326.
51. Yu J., Deshmukh H., Payton J.E., Dunham C., Scheithauer B.W., Tihan T., Prayson R.A., Guha A., Bridge J.A., Ferner R.E., Lindberg G.M., Gutmann R.J., et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin. Cancer Res. 2011, 17:1924-1934.
52. Teh M.T., Wong S.T., Neill G.W., Ghali L.R., Philpott M.P., Quinn A.G. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002, 62:4773-4780.
53. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9:873-886.
54. Xia L.M., Huang W.J., Wang B., Liu M., Zhang Q., Yan W., Zhu Q., Luo M., Zhou Z.Z., Tian D.A. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J. Cell. Biochem. 2009, 106:247-256.
55. T. Mizuno, H. Murakami, M. Fujii, F. Ishiguro, I. Tanaka, Y. Kondo, S. Akatsuka, S. Toyokuni, K. Yokoi, H. Osada, Y. Sekido, YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes, Oncogene, in press.
56. Chen Y., Zheng B., Robbins D.H., Lewin D.N., Mikhitarian K., Graham A., Rumpp L., Glenn T., Gillanders W.E., Cole D.J., Lu X., Hoffman B.J., et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int. J. Cancer 2007, 120:1511-1517.
57. Chan D.W., Yu S.Y., Chiu P.M., Yao K.M., Liu V.W., Cheung A.N., Ngan H.Y. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J. Pathol. 2008, 215:245-252.
58. Gemenetzidis E., Bose A., Riaz A.M., Chaplin T., Young B.D., Ali M., Sugden D., Thurlow J.K., Cheong S.C., Teo S.H., Wan H., Waseem A., et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009, 4:e4849.
59. Yang D.K., Son C.H., Lee S.K., Choi P.J., Lee K.E., Roh M.S. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum. Pathol. 2009, 40:464-470.
60. Lin M., Guo L.M., Liu H., Du J., Yang J., Zhang L.J., Zhang B. Nuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinoma. Histol. Histopathol. 2010, 25:1269-1275.
61. Priller M., Pöschl J., Abrão L., von Bueren A.O., Cho Y.J., Rutkowski S., Kretzschmar H.A., Schüller U. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin. Cancer Res. 2011, 17:6791-6801.
62. Pignot G., Vieillefond A., Vacher S., Zerbib M., Debre B., Lidereau R., Amsellem-Ouazana D., Bieche I. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br. J. Cancer 2012, 106:1177-1186.
63. Ma R.Y., Tong T.H., Cheung A.M., Tsang A.C., Leung W.Y., Yao K.M. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J. Cell Sci. 2005, 118:795-806.
64. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25:10875-10894.
65. Ahmad A., Wang Z., Kong D., Ali S., Li Y., Banerjee S., Ali R., Sarkar F.H. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res. Treat. 2010, 122:337-346.
66. Wang Z., Ahmad A., Li Y., Banerjee S., Kong D., Sarkar F.H. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat. Rev. 2010, 36:151-156.
67. Huynh K.M., Soh J.W., Dash R., Sarkar D., Fisher P.B., Kang D. FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. J. Cell. Physiol. 2011, 226:194-204.
68. Bao B., Wang Z., Ali S., Kong D., Banerjee S., Ahmad A., Li Y., Azmi A.S., Miele L., Sarkar F.H. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell. Biochem. 2011, 112:2296-2306.
69. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
70. Xia J.T., Wang H., Liang L.J., Peng B.G., Wu Z.F., Chen L.Z., Xue L., Li Z., Li W. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012, 41:629-635.
71. Reagan-Shaw S., Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol. Appl. Pharmacol. 2007, 224:360-368.
72. Dong X.Y., Chen C., Sun X., Guo P., Vessella R.L., Wang R.X., Chung L.W., Zhou W., Dong J.T. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res. 2006, 66:6998-7006.
73. Yang L., Hu H.M., Zielinska-Kwiatkowska A., Chansky H.A. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells. Biochem. Biophys. Res. Commun. 2010, 402:129-134.
74. Liu X., Zhang Z., Sun L., Chai N., Tang S., Jin J., Hu H., Nie Y., Wang X., Wu K., et al. MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 2011, 32:1798-1805.
75. Hasselgren P.O. Ubiquitination, phosphorylation, and acetylation - triple threat in muscle wasting. J. Cell. Physiol. 2007, 213:679-689.
76. Yang J.Y., Hung M.C. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin. Cancer Res. 2009, 15:752-757.
77. Lüpertz R., Chovolou Y., Unfried K., Kampkötter A., Wätjen W., Kahl R. The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin-mediated cytotoxicity. Carcinogenesis 2008, 29:2045-2052.
78. Polter A., Yang S., Zmijewska A.A., van Groen T., Paik J.H., Depinho R.A., Peng S.L., Jope R.S., Li X. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol. Psychiatry 2009, 65:150-159.
79. Szypowska A.A., de Ruiter H., Meijer L.A., Smits L.M., Burgering B.M. Oxidative stress-dependent regulation of Forkhead box O4 activity by nemo-like kinase. Antioxid. Redox Signal. 2011, 14:563-578.
80. Fu W., Ma Q., Chen L., Li P., Zhang M., Ramamoorthy S., Nawaz Z., Shimojima T., Wang H., Yang Y., Shen Z., Zhang Y., et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J. Biol. Chem. 2009, 284:13987-14000.
81. Oteiza A., Mechti N. The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome. J. Virol. 2011, 85:6480-6491.
82. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26:3453-3459.
83. Streubel B., Vinatzer U., Lamprecht A., Raderer M., Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005, 19:652-658.
84. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., Su X., Pui C.H., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
85. Ernst T., Score J., Deininger M., Hidalgo-Curtis C., Lackie P., Ershler W.B., Goldman J.M., Cross N.C., Grand F. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br. J. Haematol. 2011, 153:43-46.
86. Hermans K.G., van der Korput H.A., van Marion R., van de Wijngaart D.J., Ziel-van der Made A., Dits N.F., Boormans J.L., van der Kwast T.H., van Dekken H., Bangma C.H., Korsten H., Kraaij R., et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008, 68:7541-7549.
87. Goatly A., Bacon C.M., Nakamura S., Ye H., Kim I., Brown P.J., Ruskoné-Fourmestraux A., Cervera P., Streubel B., Banham A.H., Du M.Q. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod. Pathol. 2008, 21:902-911.
88. Klampfl T., Harutyunyan A., Berg T., Gisslinger B., Schalling M., Bagienski K., Olcaydu D., Passamonti F., Rumi E., Pietra D., Jäger R., Pieri L., et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118:167-176.
89. Toma M.I., Grosser M., Herr A., Aust D.E., Meye A., Hoefling C., Fuessel S., Wuttig D., Wirth M.P., Baretton G.B. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 2008, 10:634-642.
90. Banham A.H., Beasley N., Campo E., Fernandez P.L., Fidler C., Gatter K., Jones M., Mason D.Y., Prime J.E., Trougouboff P., Wood K., Cordell J.L. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001, 61:8820-8829.
91. Yang M.H., Lin B.R., Chang C.H., Chen S.T., Lin S.K., Kuo M.Y., Jeng Y.M., Kuo M.L., Chang C.C. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 2012, 31:2401-2411.
92. Craig V.J., Cogliatti S.B., Imig J., Renner C., Neuenschwander S., Rehrauer H., Schlapbach R., Dirnhofer S., Tzankov A., Müller A. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011, 117:6227-6236.
93. Datta J., Kutay H., Nasser M.W., Nuovo G.J., Wang B., Majumder S., Liu C.G., Volinia S., Croce C.M., Schmittgen T.D., Ghoshal K., Jacob S.T. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68:5049-5058.
94. Zhang Y., Li S., Yuan L., Tian Y., Weidenfeld J., Yang J., Liu F., Chokas A.L., Morrisey E.E. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev. 2010, 24:1746-1757.
95. Hu H., Wang B., Borde M., Nardone J., Maika S., Allred L., Tucker P.W., Rao A. Foxp1 is an essential transcriptional regulator of B cell development. Nat. Immunol. 2006, 7:819-826.
96. Koon H.B., Ippolito G.C., Banham A.H., Tucker P.W. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther. Targets 2007, 11:955-965.
97. Barrans S.L., Fenton J.A., Banham A., Owen R.G., Jack A.S. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004, 104:2933-2935.
98. Han S.L., Wu X.L., Wan L., Zeng Q.Q., Li J.L., Liu Z. FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig. Surg. 2009, 26:156-162.
99. Zhang Y., Zhang S., Wang X., Liu J., Yang L., He S., Chen L., Huang J. Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma. J. Clin. Pathol. 2012, 65:528-533.
100. Fox S.B., Brown P., Han C., Ashe S., Leek R.D., Harris A.L., Banham A.H. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor α and improved survival in primary human breast carcinomas. Clin. Cancer Res. 2004, 10:3521-3527.
101. Katoh M., Katoh M. Identification and characterization of human FOXN5 and rat Foxn5 genes in silico. Int. J. Oncol. 2004, 24:1339-1344.
102. Santo E.E., Ebus M.E., Koster J., Schulte J.H., Lakeman A., van Sluis P., Vermeulen J., Gisselsson D., Øra I., Lindner S., Buckley P.G., Stallings R.L., et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 2012, 31:1571-1581.
103. Mani S.A., Yang J., Brooks M., Schwaninger G., Zhou A., Miura N., Kutok J.L., Hartwell K., Richardson A.L., Weinberg R.A. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2007, 104:10069-10074.
104. Xue Y., Cao R., Nilsson D., Chen S., Westergren R., Hedlund E.M., Martijn C., Rondahl L., Krauli P., Walum E., Enerbäck S., Cao Y. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc. Natl. Acad. Sci. USA 2008, 105:10167-10172.
105. Li Y., Yang W., Yang Q., Zhou S. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype. Histol. Histopathol. 2012, 27:475-484.
106. Nishida N., Mimori K., Yokobori T., Sudo T., Tanaka F., Shibata K., Ishii H., Doki Y., Mori M. FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2011, 18:535-542.
107. Cuesta I., Zaret K.S., Santisteban P. The forkhead factor FoxE1 binds to the thyroperoxidase promoter during thyroid cell differentiation and modifies compacted chromatin structure. Mol. Cell. Biol. 2007, 27:7302-7314.
108. Landa I., Ruiz-Llorente S., Montero-Conde C., Inglada-Pérez L., Schiavi F., Leskelä S., Pita G., Milne R., Maravall J., Ramos I., Andía V., Rodríguez-Poyo P., et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet. 2009, 5:e1000637.
109. Venza I., Visalli M., Tripodo B., de Grazia G., Loddo S., Teti D., Venza M. FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma. Br. J. Dermatol. 2010, 162:1093-1097.
110. Brancaccio A., Minichiello A., Grachtchouk M., Antonini D., Sheng H., Parlato R., Dathan N., Dlugosz A.A., Missero C. Requirement of the forkhead gene Foxe1, a target of sonic hedgehog signaling, in hair follicle morphogenesis. Hum. Mol. Genet. 2004, 13:2595-2606.
111. Watson J.E., Doggett N.A., Albertson D.G., Andaya A., Chinnaiyan A., van Dekken H., Ginzinger D., Haqq C., James K., Kamkar S., Kowbel D., Pinkel D., et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 2004, 23:3487-3494.
112. Lo P.K., Lee J.S., Liang X., Han L., Mori T., Fackler M.J., Sadik H., Argani P., Pandita T.K., Sukumar S. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res. 2010, 70:6047-6058.
113. Lo P.K., Lee J.S., Sukumar S. The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. Cell. Signal. 2012, 24:316-324.
114. Nilsson J., Helou K., Kovács A., Bendahl P.O., Bjursell G., Fernö M., Carlsson P., Kannius-Janson M. Nuclear Janus-activated kinase 2/nuclear factor 1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing Forkhead box F1. Cancer Res. 2010, 70:2020-2029.
115. Feuerborn A., Srivastava P.K., Küffer S., Grandy W.A., Sijmonsma T.P., Gretz N., Brors B., Gröne H.J. The Forkhead factor FoxQ1 influences epithelial differentiation. J. Cell. Physiol. 2011, 226:710-719.
116. Zhang H., Meng F., Liu G., Zhang B., Zhu J., Wu F., Ethier S.P., Miller F., Wu G. Forkhead transcription factor FOXQ1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011, 71:1292-1301.
117. Qiao Y., Jiang X., Lee S.T., Karuturi R.K., Hooi S.C., Yu Q. FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res. 2011, 71:3076-3086.
118. Birnbaum D.J., Adélaïde J., Mamessier E., Finetti P., Lagarde A., Monges G., Viret F., Gonçalvès A., Turrini O., Delpero J.R., Iovanna J., Giovannini M., et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosom. Cancer 2011, 50:456-465.
119. Adesina A.M., Nguyen Y., Guanaratne P., Pulliam J., Lopez-Terrada D., Margolin J., Finegold M. FOXG1 is overexpressed in hepatoblastoma. Hum. Pathol. 2007, 38:400-409.
120. Shah S.P., Köbel M., Senz J., Morin R.D., Clarke B.A., Wiegand K.C., Leung G., Zayed A., Mehl E., Kalloger S.E., Sun M., Giuliany R., et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 2009, 360:2719-2729.
121. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., Liu Y., Wang Y., Liu X., Chan M.W., Liu J.Q., Love R., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286.
122. Wang L., Liu R., Li W., Chen C., Katoh H., Chen G.Y., McNally B., Lin L., Zhou P., Zuo T., Cooney K.A., Liu Y., et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009, 16:336-346.
123. Li Z., Tuteja G., Schug J., Kaestner K.H. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012, 148:72-83.
124. Westermann F., Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 2002, 184:127-147.
125. Eilers M., Eisenman R.N. Myc's broad reach. Genes Dev. 2008, 22:2755-2766.
126. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
127. Burkhart D.L., Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 2008, 8:671-682.
128. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66:9731-9735.
129. Wang M., Gartel A.L. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol. Cancer Ther. 2011, 10:2287-2297.
130. Koren S., Schatz M.C., Walenz B.P., Martin J., Howard J.T., Ganapathy G., Wang Z., Rasko D.A., McCombie W.R., Jarvis E.D., Phillippy A.M. Hybrid error correction and de novo assembly of single-molecule sequencing reads. Nat. Biotechnol. 2012, 30:693-700.